| Regulatory status | FDA-APPROVED The medicine is FDA-approved; this vial is sold strictly as a research chemical. |
|---|---|
| Mechanism | Dual GIP / GLP-1 receptor agonist |
| Developer | Eli Lilly |
| Form | Lyophilized powder · 10mg, 30mg, 60mg, 100mg |
| CAS | 2023788-19-2 |
| Purity docs | Batch-matched COA available on request — ask us. |
| Ships from | Ontario, Canada |
| Intended use | Laboratory research only. Not for human consumption. |
Tirzepatide engages two incretin pathways at once — GIP and GLP-1 — and the SURMOUNT trials showed what that combination can do. It remains the efficacy benchmark among approved medicines and the standard comparator for every investigational compound behind it.
Lyophilized vials: keep sealed, dry, and away from light and heat. Refrigeration at 2–8°C is the best default; −20°C for long-term storage. After reconstitution: refrigerate at 2–8°C and use promptly — no beyond-use date is validated.
The dual agonist that reset expectations for the entire class.
New here? Read the beginner's guide →
$15 flat shipping Canada-wide · free over $200
The active ingredient in Ozempic and Wegovy — the original once-weekly weight-loss medicine.
GLP-1 receptor agonist
A once-weekly weight-loss medicine already approved in China — still experimental in Canada and the US.
Dual GLP-1 / glucagon receptor agonist
An experimental medicine that works three ways at once — in late-stage testing, not approved anywhere yet.
Triple GIP / GLP-1 / glucagon receptor agonist
